Metabolic genotype in relation to individual susceptibility to environmental carcinogens

International Archives of Occupational and Environmental Health

Volumn 73, Issue 2, 2000, Pages 71-85

  Indulski, J A ^a   Lutz, W ^a  

^a NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

Cancer; Cytochromes P 450; Genetic polymorphism; Glutathione S transferases, N Acetyltransferases; Individual susceptibility

Indexed keywords

ALDEHYDE DEHYDROGENASE; AMINO ACID; AROMATIC AMINE; ASPARAGINE; CARCINOGEN; CODEINE; CYSTEINE; CYTOCHROME P450; DEBRISOQUINE; DEBRISOQUINE 4 HYDROXYLASE; DIMETHYLNITROSAMINE DEMETHYLASE; DNA; ETHOXYRESORUFIN DEETHYLASE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HEAT SHOCK PROTEIN 90; HEME; ISOLEUCINE; MENADIONE; MESSENGER RNA; PENTOXYRESORUFIN DEALKYLASE; PHENACETIN O DEETHYLASE; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN P53; PROTEIN TYROSINE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; THREONINE; UNINDEXED DRUG; VALINE; WARFARIN;

BIOTRANSFORMATION; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENIC ACTIVITY; CELL METABOLISM; DRUG POTENTIATION; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MULTIGENE FAMILY; POINT MUTATION; REVIEW;

EID: 0034059899     PISSN: 03400131     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00007942     Document Type: Review

References (142)

1. Abe M, Deguchi T, Suzuki T (1993) The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population. Biochem Biophys Res Commun 191: 811-816
2. Agundez JAG, Olivera M, Martinez C, Ladero JM, Benitez J (1996) Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 6: 257-259
3. Akillu E, Persson I, Bertilsson L, Rodriques F, Ingelman-Sundberg M (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in a black African population carrying duplicated and multiduplicated function CYP2D6 alleles detection. J Pharmacol Exp Ther 278: 441-446
4. Ames BN, Shigenaga MK, Gold LS (1993) DNA lesions, inducible DNA repair, and cell division: three key factors in mutagenesis and carcinogenesis. Environ Health Perspect 93: 35-44
5. Arias TD, Jorge LF, Griese E-U, Inaba TEM (1993) Polymorphic N-acetyltransferase (NAT2) in Amerindian populations of Panama and Colombia: high frequencies of M3 mutation. Pharmacogenetics 3: 328-331
6. Awasthi YC, Sharma R, Singhal SS (1994) Human glutathione S-transferases. Int J Biochem 26: 295-308
7. Badavi A, Hirvonen A, Bell DA, Lang N, Kadlubar FF (1995) Role of aromatic amine acetyltransferases NAT1 and NAT2 in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 55: 5230-5237
8. Bell DA, Taylor JA, Paulson D, Robertson CN, Mohler JL, Lucier CW (1993) Genetic risk and carcinogen exposure: a common inherited defect of carcinogen metabolism gene glutathione S-transferase M1 (GSTM1) increases susceptibility to bladder cancer. J Natl Cancer Inst 85: 1159-1164
9. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A (1995a) Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 55: 5226-5229
10. Bell DA, Stephens DA, Castranis T, Umbach DM, Watson M, Deakin M, Elder J, Hendricke C, Duncan H, Strange RC (1995b) Polyadenylation polymorfism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 55: 3537-3542
11. Bertilsson L (1995) Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 29: 192-199
12. Blum M, Grant DM, McBridge W, Heim M, Meyer UA (1990) Human-arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 9: 193-203
13. Blum M, Demierr A, Grant DM, Heim M, Meyer UA (1991) Molecular mechanism of slow acetylation in man. Proc Natl Acad Sci USA 88: 5237-5241
14. Boobis AP, Lynch AM, Murray S, De La Torre R, Solans A, Farre M, Segura J, Gooderham N-J, Davies DS (1994) CYP1A2-catalyzed conversion of dietary heterocyclic amines to their major route of metabolism in humans. Cancer Res 54: 89-94
15. Bouchardy C, Mitsunen K, Wikman H, Husgafvel-Pursiainen K, Dager P, Benhamou S, Hirvonen A (1998) N-Acetyltransferase NAT1 and NAT2 genotypes and lung cancer. Pharmacogenetics 8: 283-290
16. Brandt-Rauf PW (1997) Biomarkers of gene expression. Growth factors and oncoproteins. Environ Health Perspect 105: 807-816
17. Brockmöller J, Kerb R, Drakoulis N, Staffeldt B, Roots I (1994) Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case control study. Cancer Res 54: 4101-4111
18. Bronsen K, de Morais SMF, Meyer UA, Goldstein JA (1995) A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 5: 312-317
19. Bruning T, Lammert M, Kempkes M, Thier R, Golka K, Bolt HM (1997) Influence of polymorphisms of GSTM1 for risk of renal cell cancer in workers with long-term high occupational exposure to trichloroethene. Arch Toxicol 71: 596-599
20. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I (1995) Arylamine N-acetyltransferase (NAT2) mutations and their alleles linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57: 581-592
21. Cascorbi I, Brockmöller J, Bauer S, Reum T, Roots I (1996a) NAT2*12A (803A-G) codes for rapid arylamine N-acetylation in humans. Pharmacogenetics 6: 257-259
22. Cascorbi I, Brockmöller J, Mrozikiewicz PM, Bauer S, Loddenkemper R, Roots I (1996b) Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res 56: 3961-3966
23. Cascorbi I, Brockmöller J, Roots I (1996c) A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkage, and impact on lung cancer susceptibility. Cancer Res 56: 4965-4969
24. Chang C, Puga A (1998) Constitutive activation of the aromatic hydrocarbon receptor. Mol Cell Biol 18: 525-535
25. Christensen PM, Gotzsche PC, Bronsen K (1997) The sparteine/ debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: meta-analysis. Eur J Clin Pharmacol 51: 389-393
26. Cosma G, Crofts F, Currie D, Toniolo P, Garte JP (1993) The relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 40: 315-322
27. Daly AK, Steen VM, Fairbrother KS, Idle JR (1996a) CYP2D6 multiallelism. Methods Enzymol 272: 199-210
28. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ et al (1996b) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6: 193-261
29. Deguchi T (1992) Physiology and molecular biology of arylamine N-acetyltransferases. Biomed Res 13: 231-242
30. Deloménie C, Sica L, Grant DM, Krishnamoorthy R, Dupert JM (1996) Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics 6: 177-185
31. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 46: 594-598
32. d'Errico A, Taioli E, Chen X, Vineis P (1996) Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers 1: 149-173
33. Doll MA, Jiang W, Deitz AC, Rustan TD, Hein DW (1997) Identification of a novel allele at the human NAT1 acetyltransferase locus. Biochem Biophys Res Commun 233: 584-591
34. El-Zein RA, Zwischenberger JB, Abdel-Rahman SZ, Brekelbaum C, Au WW (1997a) Combined genetic polymorphism and risk for development of lung cancer. Mutat Res 381: 189-200
35. El-Zein RA, Zwischenberger JB, Abdel-Rahman SZ, Sankar AB, Au WW (1997b) Polymorphism of metabolizing genes and lung cancer histology: prevalence of CYP2E1 in adenocarcinoma. Cancer Lett 112: 71-78
36. Eubanks M (1994) Biomarkers: the clues to genetic susceptibility. Environ Health Perspect 102: 50-56
37. Evans DAP (1992) N-Acetyltransferase. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon Press. New York, pp 95-178
38. Fontana X, Peyrottes I, Rossi C, Leblanc Talent P, Ettore F, Namer M, Bussiere F (1998) Study of the frequencies of CYP1A1 gene polymorphisms and glutathione S-transferase mu 1 gene in primary breast cancers: an update with an additional 114 cases. Mutat Res 403: 45-54
39. Fryer AA, Zhao L, Alldersea J, Pearson WR, Strange PC (1993) Use of site directed mutagenesis of allele-specifie PCR primers to identify the GSTM1 A, GSTM1 B, GSTM1 A,B and GSTM1 null polymorphisms at the glutathione S-transferase GSTM1 locus. Biochem J 295: 313-315
40. 1. Cancer Res 54: 101-108
41. Goldstein JA, de Morais SMF (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299
42. Golka K, Prior V, Blaszkiewicz M, Cascorbi I, Schops W, Kierfeld G, Roots I (1996) Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. Scand J Work Environ Health 22: 332-338
43. Gonzalez FJ, Gelboin HV (1992) Human cytochromes P450: evolution and cDNA - directed expression. Environ Health Perspect 98: 81-85
44. Goto I, Yoneda S, Yamamoto M, Kawajiri K (1996) Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 56: 3725-3730
45. Grant DM (1993) Molecular genetics of the N-acetyltransferases. Pharmacogenetics 3: 45-50
46. Grant DM, Blum M, Demierre A, Meyer UA (1989) Nucleotide sequence of an intronless gene for a human arylamine N-acetyltransferase related to polymorphic drug acetylation. Nucleic Acid Res 17: 3978-3988
47. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Caedigk A, Yu VL, Grewal R (1997) Human acetyltransferase polymorphisms. Mutat Res 376: 61-70
48. Guengerich FP (1998) The environmental genome project: functional analysis of polymorphisms. Environ Health Perspect 106: 365-368.
49. Guengerich FP, Shimada T(1998) Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res 400: 201-214
50. Hanioka N, Kimura S, Meyer UA, Gonzalez FJ (1990) The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 47: 994-1001
51. Harris MJ, Coggan M, Langton L, Wilson SR, Board PG (1998) Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics 8: 27-31
52. Harrison DJ, Cantlay AM, Rae F, Lamb D, Smith CA (1997) Frequency of glutathione S-transferase M1 deletion in workers with emphysema and lung cancer. Human Exp Toxicol 16: 356-360
53. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266: 1821-1828
54. Hayashi S, Watanabe J, Nakachi K, Kawajiri K (1991) Genetic linkage of lung cancer associated Msp1 polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene. J Biochem 110: 407-411
55. Hayashi S, Watanabe J, Kawajiri K (1992) High susceptibility to lung cancer analysed in terms of combined genotypes of P4501A1 and mu class glutathione S-transferase genes. Jpn J Cancer 83: 866-870
56. Hayesh RB, Bi W, Rothman N, Broly F, Caporaso N, Feng P, You X, Yin S, Woosley RL, Meyer UA (1993) N-Acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 14: 675-678
57. Heagerty AHM, Fitzgerald D, Smith A (1994) Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours. Lancet 343: 266-268
58. Heckbert SR, Weiss NS, Horning SK, Eaton DC, Motulsky A (1992) Glutathione S-transferase and epoxide hydrolase activity in human leucocytes in relation to risk of lung cancer and other smoking related cancers. J Natl Cancer Inst 84: 414-422
59. Hickman D, Sim E (1991) N-Acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem Pharmacol 42: 1007-1014
60. Hirvonen A (1997a) Combinations of susceptible genotypes and individual responses to toxicants. Environ Health Perspect 105 [Suppl 4]: 755-758
61. Hirvonen A (1997b) Genetic factors in individual responses to environmental exposures. J Occup Environ Med 37: 37-43
62. Hirvonen A, Husgafvel-Pursiainen K, Antila S, Vainio H (1993) The GSTMI null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 14: 1479 1481
63. Hirvonen A, Pelin K, Tammiletho I, Karjalainen A, Mattson K, Linnainmaa K (1995) Inherited GSTM1 and NAT2 defects as concurrent risk modifiers for asbestos-associated human malignant mesothelioma. Cancer Res 55: 2981-2983
64. Hussey AJ, Kerr LA, Gronshaw AD, Harrison DJ, Hayes JD (1991) Variation in the expression of mu-class glutathione S-transferase isoenzymes from human skeletal muscle. Evidence for the existence of heterodimers. Biochem J 273: 323-332
65. Indulski JA, Lutz W (1997) Molecular epidemiology: cancer risk assessment using biomarkers for detecting early health effects in individuals exposed to occupational and environmental carcinogens. Rev Environ Health 12: 179-190
66. Ishibe N, Wiencke JK, Zuo Z-F, McMillan A, Spitz MR, Kelsey KT (1998) Polymorphisms in the N-acetyltransferase 1 (NAT1) gene and lung cancer risk in a minority population. Biomarkers 3: 219-226
67. Jaskula-Sztul R, Reinikainen M, Husgafvel-Pursiainen K, Sznieja Z, Szyfter W, Szyfter K, Hirvonen A (1998) Glutathione S-transferase M1 and T1 genotypes and susceptibility to smoking related larynx cancer. Biomarkers 3: 149-155
68. Kadlubar FF (1994) Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acelyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. Drug Metab Rev 26: 37-46
69. Kadlubar FF, Butler MA, Kaderlik KR, Chou H-C, Lang NP (1992) Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect 98: 69-74
70. Karran P, Bignami M (1994) DNA damage tolerance, mismatch repair and genome instability. Bioessays 16: 833-839
71. Kato R, Yamazoe Y (1994) Metabolic activation of N-hydroxylated metabolites of carcinogenic and mutagenic arylamines and arylamides by esterification. Drug Metab Rev 26: 413-430
72. Kawajiri K, Eguch H, Nakachi K, Sekiya T, Yamamoto M (1996) Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 54: 72-76
73. Kelsey KT, Spitz MR, Zuo ZF, Wiencke JK (1997) Polymorphisms in the glutathione S-transferase class mu and theta genes interact and increase susceptibility to lung cancer in minority populations (Texas, United States). Cancer Causes Control 8: 554-559
74. Kempkes M, Golka K, Reich S, Reckwitz T, Bolt HM (1996a) Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch Toxicol 71: 123-126
75. Kempkes M, Wiebel FA, Golka Heitmann P, Bolt HM (1996b) Comparative genotyping and phenotyping of glutathione S-transferase GSTT1. Arch Toxicol 70: 306-309
76. Kimura M, Ieiri I, Mamiya K, Urae F, Higuchi S (1998) Genetic-polymorphism of cytochrome P450s, CYP2C19 and CYP2C9 in Japanese population. Ther Drug Monit 20: 243-247
77. Kiyohara C, Hirohata T, Inutsuka S (1996) The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res 87: 18-24
78. Knudson AG (1993) Antioncogenes and human cancer. Proc Natl Acad Sci USA 90: 10914-10921
79. Koop DR, Cederbaum AI, Song BJ, Ingelman-Sundberg M, Nariji A (1996) Ethanol-inducible cytochrome P450 (CYP2E1): biochemistry, molecular biology and clinical relevance: 1996 update. Alcohol Clin Exp Res 20: 138-146
80. Kroemer HK, Eichelbaum M (1995) "It's the genes, stupid." Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56: 2285-2298
81. Ladero JM, Gonzalez JF, Benitez J, Vargas E, Fernandez MJ, Baki W, Diaz-Rubio M (1991) Acetylator polymorphism in human colorectal carcinoma. Cancer Res 51: 2098-2100
82. Lafuente A, Pujol F, Carreterro P, Villa JP, Luchi A (1993) Human glutathione S-transferuse μ (GSTμ) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett 68: 49-54
83. Lee SW, Jang IJ, Shin SG, Lee KH, Yim DS, Kim SW, Oh SJ, Lee SH (1994) CYP1A2 activity as a risk factor for bladder cancer. J Korean Med Sei 9: 482-489
84. Liang Q, He J, Fulco A (1995) The role of barbie box sequences as cis-acting elements involved in the barbiturate-mediated induction of cytochromes P450BM-1 and P450BM-2 in Bucillus megaterium. J Biol Chem 270: 4438-4450
85. Lin HJ, Han C-Y, Lin BK, Hardy S (1993) Slow acetylator mutation in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics, and Whites: Application to metabolic epidemiology. Am J Human Genet 52: 827-834
86. Lin HJ, Han C-Y, Lin BK, Hardy S (1994) Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 4: 125-134
87. Lin L, Yang F, Ye Z, Xu E, Yang C, Zhang C, Wu D, Nebert DW (1990) Case control study of cigarette smoking and primary hepatoma in an aflatoxin endemic region of China. A protective effect. Pharmacogenetics 1: 79-85
88. Maier A, Micka J, Miller K, Denko T, Chang C-Y, Nebert DN, Puga A (1998) Aromatic hydrocarbon receptor polymorphism: development of new methods to correlate genotype with phenotype. Environ Health Perspect 106: 421-426
89. Martinez C, Agundez JA, Olivera M, Martin R, Ladero JM, Benitez J (1995) Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 5: 207-214
90. Meyer UA (1994) The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol 46 [Suppl 1]: 409-415
91. Meyer UA, Zanger UM (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37: 269-296
92. Micka J, Milatovich A, Menon A, Grabowski CA, Puga A, Nebert DW (1997) Human Ah receptor (AHR) gene: localization to 7p17 and suggestive correlation of polymorphism with CYP1A1 inducibility. Pharmacogenetics 7: 95-101
93. Mrozikiewicz PM, Cascorbi I, Brockmöller J, Roots I (1996) Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clin Pharmacol ther 59: 376-382
94. Nakachi K, Hayashi S, Kawajiri K, Imai K (1995) Association of cigarette smoking and CYP1A1 polymorphisms with adenocarcinoma of the lung by grades of differentiation. Carcinogenesis 16: 2209-2213
95. Nakajima M, Yokoi T, Mitzunami M, Shin S, Kudlubar FF, Kamataki T (1994) Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolite: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 3: 413-521
96. Nebert DW (1994) Drug-metabolizing enzymes in ligand-modulated transcription. Biochem Pharmacol 47: 25-37
97. Nebert DW, Johnson EP (1991) P450 gene nomenclature based on evolution. In: Waterman MR, Johnson EP (eds) Methods Enzymology. Academic Press, New York, pp 3-11
98. Nebert DW, McKinnon RA, Puga A (1996) Human drug metabolizing enzyme polymorphisms effects on risk of toxicity and cancer. DNA Cell Biol 15: 273-280
99. Nelson DR, Kamataki T, Waxman DJ (1993) The P450 superfamily: up date on new sequences, gene mapping, accession numbers, early trivial names, and nomenclature. DNA Cell Biol 12: 1-51
100. Okkels H, Sigsgaard T, Wolf H, Autrup H (1997) Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 6: 225-231
101. Oyama T, Kawamoto T, Miaoue T, Yasumoto K, Kodama Y, Mitsudomi T (1997) N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. Anticancer Res 17: 577-581
102. Ozawa S, McDaniel LP, Tang Y-M, Schoket B, Vincze I, Kostic S, Kadlubar FF (1997) CYP2C9 and GSTP1 genetic polymorphisms in patients with smoking-related lung cancer. Proc Annu Meet Am Assoc Cancer Res 38: A1427
103. Pelkonen O Raunio H (1997) Metabolic activation of toxins. Tissue-specific expression and metabolism in target organs. Environ Health Perspect 105 [Suppl 4]: 767-774
104. Penible S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB (1994) Human glulathione S-transferase theta (GST1): cDNA cloning and the characterisation of a genetic polymorphism. Biochem J 300: 271-276
105. Perera FP (1997) Environment and cancer: who are susceptible? Science 278: 1068-1073
106. Person I, Johansson I, Ingelman-Sundherg M (1997) In vivo kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun 231: 227-230
107. Pitot WC, Dragan YP (1996) Chemical carcinogenesis. In: Klaassen CD, Amdur MO, Doull J (eds) Casarett and Doull's toxicology. The basis science of poisons. McGraw-Hill Health Professions Division, New York, pp 201-267
108. Pratt WB (1997) The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Annu Rev Pharmacol Toxicol 37: 297-326
109. Puga A, Nebert DW, McKinnon RA, Menon AG (1997) Genetic polymorphisms in human drug metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance. Crit Rev Toxicol 27: 1999-2022
110. Rannuug A, Alexandrie A-K, Persson I, Ingelman-Sundberg M (1996) Genetic polymorphism of cytochromes P-4501A1, 2D6 and 2E1: regulation and toxicological significance. J Occup Environ Med 37: 25-36
111. Rebbeck TR (1997) Molecular epidemiology of the human glutathione S-transferase genotype GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 6: 733-743
112. Rhodes N, Paules RS, Roberts JD (1995) Molecular mechanisms of environmental carcinogenesis. Environ Health Perspect 103: 504-506
113. Risch A, Wallace DM, Bathers S, Sim E (1995) Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 4: 231-236
114. Rodriquez JW, Kirlin WG, Ferguson RJ (1993) Human acetylator genotype-relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Arch Toxicol 67: 4045-452
115. Rushmore TH, Picket CB (1993) Glutathione S-transferases, structure, regulation and therapeutic implications. J Biol Chem 268: 11475-11478
116. Ryberg D, Skaug V, Hewer A, Phillips DH, Harries LW, Wolf CR, Ogreid D, Ulvik A, Vu P, Haugen A (1997) Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis 18: 1285-1289
117. Saarikoski ST, Voho A, Reinikainen M, Anttila S, Karjalainen A, Malaveille C, Vainio H, Husgafvel-Pursiainen K, Hirvonen A (1998) Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int J Cancer 77: 516-521
118. Schnakenberg E, Ehlers C, Feyerabend W, Werdin R, Hubotter R, Dreikom K, Schloot W (1998) Genotyping of the polymorphic N-acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patients. Clin Genet 53: 396-402
119. Schoket B, Phillips DH, Kostic S, Vincve I (1998) Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 Msp1 and GSTM1 genotypes in lung cancer patients. Carcinogenesis 19: 841-846
120. Schuetz JD, Beach BL, Guzelian PJ (1994) Selective expression of cytochrome P4503A mRNAs in embryonic and adult human liver. Pharmacogenetics 4: 11-20
121. Shields PC (1993) Inherited factors and environmental exposures in cancer risk. J Occup Med 35: 34-41
122. Smith CAD, Moss JE, Gough AC, Spurr NK, Wolf CR (1992) Molecular genetic analysis of the cytochrome P450 debrisoquine hydroxylase locus and association with cancer susceptibility. Environ Health Perspcct 98: 107-112
123. Smith CAD, Smith G, Wolf CR (1994) Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer 30A: 1935-1941
124. Smith TJ, Lino A, Wang LD, Yang GY, Stareic S, Philbert M, Yang CS (1998) Characterization of xenobiotic-metabolizing enzymes and nitrosamine metabolism in the human esophagus. Carcinogenesis 19: 667-772
125. Sogawa K, Fujii-Kuriyama Y (1997) Ah receptor, a novel ligand-activated transcription factor. J Biochem (Tokyo) 122: 1075-1079
126. Spitz MR, Body ML (1993) Genetic susceptibility to cancer. Cancer 72: 991-995
127. Strange RC, Lear JT, Fryer AA (1998) Polymorphism in glutathione S-transferase loci as a risk factor for common cancers. Arch Toxicol 20 [Suppl]: 419-428
128. Taioli E, Crofts F, Trachmun J, Bayo S, Toniolo P, Garte SJ (1995) Racial differences in CYP1A1 genotype and function. Toxicol Lett 77: 357-362
129. To-Figueras J, Gene M, Gomez-Catalan J, Galan MC, Firvida J, Fuentes M, Rodamilans M, Estape J, Corbella J (1996) Glutathione S-transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 5: 337-342
130. To-Figueras J, Gene M, Gomez-Catalan J, Galan MC, Fuentes M, Ramon JM, Rodamilans M, Huguet E, Corbella J (1997) Glutathione S-transferase M1 (GSTM1) and T, (GSTT1) polymorphisms and lung cancer among Northwestern Mediterraneans. Carcinogenesis 18: 1529-1533
131. Tucker GT (1994) Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 46 [Suppl 1]: 417-424
132. Van Damme K, Casteleyn L (1998) Ethical, social and scientific problems related to the application of genetic screening and genetic monitoring tor workers in the context of a European approach to health and safety at work. Med Lav 89 [Suppl 1]: S1-S72
133. Vatsis KP, Weber WW (1993) Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 301: 71-76
134. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV et al (1995) Nomenclature for N-acetyltransferases. Pharmacogenetics 5: 1-17
135. Wang XW, Harris CC (1997) p53 Tumor suppressor gene: clues to molecular Carcinogenesis. J Cell Physiol 178: 247-255
136. Wolf CR, Smith CAD, Bishop T, Forman D, Gough AC, Spurr NK (1994) CYP2D6 genotyping and the association with lung cancer susceptibility. Pharmacogenetics 4: 104-106
137. Wolf CR, Smith CAD, Forman D (1994) Metabolic polymorphisms in carcinogen metabolizing enzymes and cancer susceptibility. In: Ponder BAJ (ed) Genetics of malignant disease. Br Med Bull, pp 718-731
138. Wong LL (1998) Cytochrome P450 monooxygenases. Curr Opin Chem Biol 2: 263-268
139. Wrighton SA, Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22: 1-21
140. Yamazaki H, Inoue K, Shimada T (1998) Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica 28: 103-115
141. Yang E, Jeong-Sook V, Ishizaki H, Hang Y (1990) Cytochrome P450IIE1 roles in nitrosoamine metabolism and mechanisms of regulation. Drug Metab Rev 22: 147-159
142. Zhong S, Wyllie AM, Barnes D, Wolf CR, Spurr NK (1993) Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 14: 1821-1824